🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Fantastic late breaker session at #HeartFailure2025 ‼️ 🇳🇴🇸🇪🇮🇹 doing really well on #GDMT uptake - especially after the 2021 European Society of Cardiology guidelines, including improvements in outcomes 👏🏻 ⭐️⭐️⭐️ Kristian Berge Riccardo M. Inciardi, MD, PhD #FelixLindberg

Intriguing new data out in JACC Journals in time for #HeartFailure2025 from ATTRibuteCM Stabilization of TTR (prealbumin) leads to immediate & sustained rise in TTR levels Degree of rise identifies those likely to derive mortality protection from TTR stabilizers #MedIQHF2025

A simplified approach for diagnosing #HFpEF by assessing the left atrium and natriuretic peptides A simplified approach for diagnosing heart failure with preserved ejection fraction by assessing the left atrium and natriuretic peptides onlinelibrary.wiley.com/doi/10.1002/ej… #EJHF #HFA_ESC

🔥#LBCT #VELOCITY_study examined a simplified #vericiguat dose titration pathway for #HFrEF >9 of 10 pts safely tolerated a 5 mg starting dose (bypassing traditional 2.5 mg step) #SimPub European Society of Cardiology Journals #EJHF EJHF Editor-in-Chief #HeartFailure2025 Duke Clinical Research Institute 🔗onlinelibrary.wiley.com/doi/10.1002/ej…

Incident heart failure is common and underrecognized in patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease Kara Wegermann Marat Fudim, MD MHS onlinelibrary.wiley.com/doi/10.1002/ej… #EJHF Henry Han Amr Abdin Giuseppe Galati

HFpEF affects ~4M in the U.S. Once lacking therapies, HFpEF is now seeing rapid progress—with SGLT2i, Ns-MRAs, and GLP-1 RAs offering hope, especially for the obesity phenotype. (link.springer.com/article/10.100…). #HREV Josephine Harrington, MD Marc Bonaca MD MPH Andrew J Sauer MD orlyvardeny Mario Enrico Canonico

#Albuminuria as a diagnostic criterion and a therapeutic target in heart failure and other #CVDs BiykemBozkurt onlinelibrary.wiley.com/doi/10.1002/ej… Henry Han Amr Abdin Giuseppe Galati #EJHF

Finerenone reduces CKD progression & CVD in T2D (FIDELIO/FIGARO), driven by ↓ HF hospitalizations. FINEARTS-HF shows benefit in HFmrEF/HFpEF. More to come from MOONRAKER in HF irrespective of EF (link.springer.com/article/10.100…). #HREV Pam R. Taub, MD❤️💃🏻 Steve Greene Marat Fudim, MD MHS Andrew J Sauer MD

Presented at #ERA25: In the CONFIDENCE trial in persons with chronic kidney disease and type 2 diabetes, combination therapy with finerenone and empagliflozin led to a greater reduction in the urinary albumin-to-creatinine ratio than either drug alone. Full trial results:

#CONFIDENCE tested combination SGLT2i + nsMRA on excellent background medical therapy including ~100% RASi & >25% GLP-1RA Initial data to test concept of “quadruple therapy” pillar-based approach in #CKD & #T2D

Combination therapy as a new standard of care in CKD - multiple trials testing new therapies in combo with SGLT2i - ARCTIC/PACIFIC trials: Baxdrostat/dapa vs. dapa - EASi-KIDNEY: Vicadrostat/empa vs. empa - ZENITH-HP: Zibotentan/dapa vs. dapa doi.org/10.1093/ndt/gf… #ERA25

🗞️ Insights into the European #heartfailure epidemiology European Society of Cardiology Journals Giuseppe Galati Amr Abdin Henry Han bit.ly/44665SJ

Our new #EJHF analysis from #DELIVER, #PARAGON-HF and #TOPCAT-Americas show that the diagnostic process to rule out ATTR-CM should not necessarily delay the introduction of conventional HF medical therapies. doi:10.1002/ejhf.3698

Pooled analysis of obesity and kidney outcomes from 4 HFpEF RCTs now in JACC Journals 👥 n=16,919 ⬆️ waist circumference ➡️ higher kidney risk🫘🏥 ⬆️ waist-to-height ratio ➡️ higher kidney risk 🫘🏥 But not for BMI 🤔 sciencedirect.com/science/articl… Muthu Vaduganathan Tor Biering-Sørensen, MD, MSc, MPH, PhD

From ignored to essential: #HeartFailure with improved EF isn’t a footnote anymore. This #JACC review charts a path from vague definitions to clinical clarity. jacc.org/doi/10.1016/j.… #HFimpEF #LVEF

HFimpEF is on the rise, but recovery isn’t the end of the story. Our latest review dives into what we know (and don’t) about its prognosis, treatment, and outcomes jacc.org/doi/full/10.10…

Presented at #ADASciSessions: In the ACHIEVE-1 phase 3 trial, the oral small-molecule GLP-1 receptor agonist orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with early type 2 diabetes. Full trial results:

Rationale, Design, and Baseline char. of KP-VACCINATE out in AmericanHeartJ. ~3.8 Million adults randomized in 2 integrated learning healthcare systems in ~4 weeks. To our knowledge, the 🌟largest RCT ever🌟 & fully embedded in routine case. Results soon sciencedirect.com/science/articl…

🫀 Study by Camilla Ottosen from CTCPR Trials & CIRL : Diastolic dysfunction in hypertension is a key precursor to HFpEF — but remains hard to diagnose and treat. 🔍 Review covers pathophysiology, echo tools (strain, TDI) & clinical challenges. 🔗 doi.org/10.1093/ehjci/…

🚨 Finerenone Approved by US FDA in HF based on #FINEARTSHF Finerenone (Kerendia) is a non-steroidal MRA indicated to reduce the risk of CV death, hospitalization for HF, & urgent HF visits in adult patients with HF with LVEF>= 40% bayer.com/media/en-us/us…